[{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Roche Diagnostics GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Roche Diagnostics GmbH"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"},{"orgOrder":0,"company":"Inotrem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Nangibotide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : LR12 (nangibotide) targets the immunoreceptor TREM-1 (triggering receptor expressed on myeloid cells-1). It is under phase 2 clinical development for the treatment of Septic Shock.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          January 08, 2024

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function, and improve post septic shock survival.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          October 25, 2022

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Nangibotide is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response and improve post septic shock survival. ASTONISH demonstrates that TREM-1 modulation with nangibotide improves respiratory, cardiovascular and renal...

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          October 13, 2022

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : The ASTONISH Phase IIB study aims at demonstrating safety and clinical efficacy of nangibotide in septic shock patients. It is a global, multicentric study conducted in 48 centers.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          June 10, 2021

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Inotrem’s Phase IIa clinical trial which takes place in France, Belgium and the United States will determine the safety, tolerability and potential signals of efficacy of nangibotide, the company’s lead product, in critically ill COVID-19 patients.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          December 24, 2020

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Nangibotide is a TREM-1 pathway inhibitor with multiple potential indications, such as septic shock and myocardial infarction. TREM-1 is an immunomodulatory receptor found on innate immune cells, which increases and maintains inflammation.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          July 23, 2020

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Nangibotide is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          June 12, 2020

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Undisclosed

                          January 21, 2020

                          Lead Product(s) : Nangibotide

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : Roche Diagnostics GmbH

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank